Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sales Increase by 9.9%, Net Profits Return to Black: NBI
May 8, 2012
- OrphanPacific Focuses on Building Detailing Form: President Ichikawa
May 8, 2012
- Eisai US Subsidiary Concludes Research Agreement with UK Venture for Identifying Target Molecules for New Cancer Drugs
May 8, 2012
- Daiichi Sankyo to Aim for Early Market Penetration for Ranmark in Copromotion with AZ
May 7, 2012
- The Growing Presence of Foreign-Affiliates (1)
May 7, 2012
- GSK Files Ofatumumab for Treatment of CLL
May 7, 2012
- DSP Aims to Enhance Its Presence in Field of Oncology by Developing First-in-Class Drugs
May 7, 2012
- MHLW Approves Sanofi Pasteur’s Imovax Polio SC Injection
May 7, 2012
- Astellas Collaborates with US Company in New “Multi-Track R&D Approach”
April 27, 2012
- 90% of Pharmacies Receive Generic Name Prescriptions with Loxoprofen as Most Frequently Prescribed Drug: Survey
April 27, 2012
- DSP Completes Acquisition of BBI, Bolsters Oncology Business
April 27, 2012
- Boehringer Ingelheim to Shift to Independent Marketing in Japan for Upcoming New Products
April 27, 2012
- Seikagaku Terminates Agreement with Finland’s Biotie
April 26, 2012
- Latuda Shows Usefulness for Bipolar I Depression in 2 PIII Clinical Trials: DSP
April 26, 2012
- R-Tech Ueno Completes PI Study for Treatment of Hypotrichosis of the Eyelashes
April 26, 2012
- New COPD Treatment Meets Primary Endpoints in Fourth PIII Trial: Sosei Group
April 26, 2012
- Hisamitsu Fails to Obtain Expected Results in Domestic PIII Study for Tinea Unguium Treatment
April 26, 2012
- Takeda Launches Renal Anemia Drug Omontys in US
April 26, 2012
- 50% of Doctors Obtain Information on New Drugs From MRs: Survey
April 25, 2012
- Generics Aimed for Early Stage Sales of 10 Billion Yen, in the Black for Establishing Base: Daiichi Sankyo Espha President Yoshiwaka
April 25, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…